Latest News and Press Releases

SINGAPORE, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recently, Intercont (Cayman) Limited (hereinafter referred to as "Intercont") released its 2026 strategic outlook and growth plan, positioning this year...

CINCINNATI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end...

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting...

Recommendation Highlights Strategic Benefits and Value Creation of Merger The Board of Directors Urges Shareholders to Vote by February 9, 2026, at 11:59 p.m., ET MIDDLEFIELD, Ohio, Jan. 30, 2026 ...

FORT SMITH, Ark., Jan. 22, 2026 (GLOBE NEWSWIRE) -- The Endeavor Investor Group (together with its affiliates, “Endeavor” or “we”) today issued the following statement in response to the lawsuit...

Jagex Marks RuneScape’s 25th Year With RS25, Delivering Record Investment, a Dedicated Game Integrity Roadmap, New Game Modes, and Much More

Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential...

DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential...

MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Troilus Mining Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5) (“Troilus” or the “Company”), is pleased to provide a review of its key accomplishments in 2025...